Aman Chauhan, MD

Articles by Aman Chauhan, MD

Long-Term Impact of RLEs and Final Thoughts

ByAman Chauhan, MD,Andrew Hendifar, MD, MPH,Heloisa P. Soares, MD, UNM Comprehensive Cancer Center,Ghassan El-Haddad, MD

July 27th 2026

Dr. El-Haddad identifies transparency as the most important long-term impact of establishing RLE terminology and expanding the 505(b)(2) pathway.

Patient Education, Trial Design, Post-Market Surveillance, and Adoption Barriers

ByAman Chauhan, MD,Andrew Hendifar, MD, MPH,Heloisa P. Soares, MD, UNM Comprehensive Cancer Center,Ghassan El-Haddad, MD

July 20th 2026

Dr. Soares frames patient education conversations around reassurance and clarity.

Clinical Implementation: RLE Supply Chain, Institutional Readiness, and Access

ByAman Chauhan, MD,Andrew Hendifar, MD, MPH,Heloisa P. Soares, MD, UNM Comprehensive Cancer Center,Ghassan El-Haddad, MD

July 20th 2026

Dr. Soares identifies the most clinically important benefit of having multiple RLE options: immediate availability for patients who are clinically ready for radioligand therapy but face delays due to drug supply or shipping constraints.

Education Strategies and Evidence Interpretation Surrounding RLE Terminology

ByAman Chauhan, MD,Andrew Hendifar, MD, MPH,Heloisa P. Soares, MD, UNM Comprehensive Cancer Center,Ghassan El-Haddad, MD

July 13th 2026

Dr. El-Haddad recommends a 2-level approach to promoting RLE terminology adoption.

RLE Terminology in Clinical Practice and Tumor Boards

ByAman Chauhan, MD,Andrew Hendifar, MD, MPH,Heloisa P. Soares, MD, UNM Comprehensive Cancer Center,Ghassan El-Haddad, MD

July 13th 2026

Dr. Hendifar describes how RLE terminology will evolve in tumor board discussions.

Introducing Radioligand Equivalent Terminology

ByAman Chauhan, MD,Andrew Hendifar, MD, MPH,Heloisa P. Soares, MD, UNM Comprehensive Cancer Center,Ghassan El-Haddad, MD

July 6th 2026

Dr. Hendifar explains the rationale for proposing the term radioligand equivalent (RLE).

Advantages of the 505(b)(2) Pathway and Bridging Evidence Requirements

ByAman Chauhan, MD,Andrew Hendifar, MD, MPH,Heloisa P. Soares, MD, UNM Comprehensive Cancer Center,Ghassan El-Haddad, MD

July 6th 2026

Dr. Hendifar explains the specific advantages the 505(b)(2) pathway offers for radiopharmaceutical development.

Multidisciplinary Communication and FDA Approval Pathway Fundamentals

ByAman Chauhan, MD,Andrew Hendifar, MD, MPH,Heloisa P. Soares, MD, UNM Comprehensive Cancer Center,Ghassan El-Haddad, MD

Published: June 30th 2026 | Updated: June 30th 2026

Dr. Soares addresses how understanding regulatory pathways benefits the multidisciplinary teams managing patients with NETs. A shared understanding of pathway terminology, particularly what a 505(b)(2) product represents, creates a common language among nuclear medicine physicians, medical oncologists, pharmacists, and radiation oncologists. This clarity reduces confusion about whether a therapy is truly novel, generic, or something in between, and directly improves the efficiency of tumor board discussions, formulary committee reviews, and patient counseling. Without this shared vocabulary, discussions stall on terminology rather than advancing to the clinically important questions of patient selection, access, and operational implementation.

Evolution of Radioligand Therapy in NETs

ByAman Chauhan, MD,Andrew Hendifar, MD, MPH,Heloisa P. Soares, MD, UNM Comprehensive Cancer Center,Ghassan El-Haddad, MD

Published: June 30th 2026 | Updated: June 30th 2026

Dr. Aman Chauhan introduces the program on radioligand equivalents and the 505(b)(2) pathway in neuroendocrine tumor (NET) treatment, joined by Dr. Andrew Hendifar, Dr. Heloisa Soares (medical director of the theranostics program at University of Utah), and Dr. Ghassan El-Haddad (vice chair for radiopharmaceutical and nuclear oncology at Moffitt Cancer Center, nuclear medicine physician and interventional radiologist).

Phase I data from the DAREON-7 trial evaluating obrixtamig, a DLL3/CD3 T-cell engager, in combination with platinum-based chemotherapy plus etoposide as first-line therapy for DLL3-positive neuroendocrine carcinomas

ByAman Chauhan, MD

April 30th 2026

Obrixtamig in combination with platinum-based chemotherapy demonstrated encouraging clinical activity in patients with DLL3-positive neuroendocrine carcinomas, with high response rates and durable disease control. The regimen showed a manageable safety profile, with adverse events consistent with its mechanism and no unexpected toxicities. These findings support further development of this combination as a potential first-line treatment option.

Theranostics and Management of NETS Going Forward

ByNamrata (Neena) Vijayvergia, MD,Junaid Arshad, MD, MS,Aman Chauhan, MD,Andrew E. Hendifar, MD,Shagufta Shaheen, MD

January 14th 2026

Discover the future of cancer treatment with innovative therapies and groundbreaking research in radiopharmaceuticals and theranostics.

CAR-T and Radioligand Therapies for Treatment of NETS

ByNamrata (Neena) Vijayvergia, MD,Junaid Arshad, MD, MS,Aman Chauhan, MD,Andrew E. Hendifar, MD,Shagufta Shaheen, MD

January 7th 2026

Experts discuss the promising future of CAR-T therapy and radioligand treatments for neuroendocrine tumors, highlighting new trials and potential breakthroughs.

Sequencing and Place of Cabozantinib in NETS Treatment Algorithm

ByNamrata (Neena) Vijayvergia, MD,Junaid Arshad, MD, MS,Aman Chauhan, MD,Andrew E. Hendifar, MD,Shagufta Shaheen, MD

January 7th 2026

Experts discuss the challenges of sequencing treatments like cabozantinib and managing side effects in patients with metastatic disease.

CABINET Study and Cabozantinib for Treatment of NETS

ByNamrata (Neena) Vijayvergia, MD,Junaid Arshad, MD, MS,Aman Chauhan, MD,Andrew E. Hendifar, MD,Shagufta Shaheen, MD

December 23rd 2025

Dr. Chauhan discusses the groundbreaking CABINET trial, revealing its impact on treating neuroendocrine tumors and the future of oncology research.

Patient with NETS Post PRRT in Second-Line

ByNamrata (Neena) Vijayvergia, MD,Junaid Arshad, MD, MS,Aman Chauhan, MD,Andrew E. Hendifar, MD,Shagufta Shaheen, MD

December 23rd 2025

Experts discuss treatment options for a young patient with pancreatic neuroendocrine tumor and liver metastases, focusing on targeted therapies.

Treatment Options for High Grade (Grade 3) NETS

ByNamrata (Neena) Vijayvergia, MD,Junaid Arshad, MD, MS,Aman Chauhan, MD,Andrew E. Hendifar, MD,Shagufta Shaheen, MD

December 16th 2025

Doctor Hendifer discusses the diverse therapies for neuroendocrine neoplasms, emphasizing individualized treatment based on patient needs and disease characteristics.

Sequencing of Systemic NETS Treatments

ByNamrata (Neena) Vijayvergia, MD,Junaid Arshad, MD, MS,Aman Chauhan, MD,Andrew E. Hendifar, MD,Shagufta Shaheen, MD

December 16th 2025

Experts discuss advanced treatment options for neuroendocrine tumors, highlighting PRRT, mTOR inhibitors, and emerging therapies for improved patient outcomes.

Inadequate Response and Second-Line Treatment of NETS

ByNamrata (Neena) Vijayvergia, MD,Junaid Arshad, MD, MS,Aman Chauhan, MD,Andrew E. Hendifar, MD,Shagufta Shaheen, MD

December 9th 2025

Oncology treatment decisions hinge on tumor biology and patient factors, emphasizing a multidisciplinary approach for optimal care.

Site of Origin and Treatment of NETS

ByNamrata (Neena) Vijayvergia, MD,Junaid Arshad, MD, MS,Aman Chauhan, MD,Andrew E. Hendifar, MD,Shagufta Shaheen, MD

December 9th 2025

Experts discuss treatment strategies for neuroendocrine tumors, emphasizing personalized approaches based on tumor grade, symptoms, and patient health.

First-Line Treatment and Standard of Care for NETS

ByNamrata (Neena) Vijayvergia, MD,Junaid Arshad, MD, MS,Aman Chauhan, MD,Andrew E. Hendifar, MD,Shagufta Shaheen, MD

December 2nd 2025

Explore the complexities of treating neuroendocrine tumors, focusing on patient-specific strategies and the role of somatostatin analogs.

Prognostic Factors for Neuroendocrine Tumors

ByNamrata (Neena) Vijayvergia, MD,Junaid Arshad, MD, MS,Aman Chauhan, MD,Andrew E. Hendifar, MD,Shagufta Shaheen, MD

December 2nd 2025

Experts discuss key factors influencing disease prognosis, emphasizing differentiation, growth pace, and disease burden in treatment decisions.

Role of Biomarkers in Diagnosis and Management of NETS

ByNamrata (Neena) Vijayvergia, MD,Junaid Arshad, MD, MS,Aman Chauhan, MD,Andrew E. Hendifar, MD,Shagufta Shaheen, MD

November 21st 2025

Experts discuss the evolution of neuroendocrine tumor classification, highlighting its clinical implications and the importance of standardized treatment approaches.

Early Diagnosis of Neuroendocrine Tumors

ByNamrata (Neena) Vijayvergia, MD,Junaid Arshad, MD, MS,Aman Chauhan, MD,Andrew E. Hendifar, MD,Shagufta Shaheen, MD

November 21st 2025

Experts discuss the evolution of neuroendocrine tumor classification, highlighting its impact on diagnosis, treatment, and clinical implications.

Imaging Modalities for Neuroendocrine Tumors

ByNamrata (Neena) Vijayvergia, MD,Junaid Arshad, MD, MS,Aman Chauhan, MD,Andrew E. Hendifar, MD,Shagufta Shaheen, MD

November 14th 2025

Imaging Modalities for Neuroendocrine Tumors

Classification of Neuroendocrine Tumors

ByNamrata (Neena) Vijayvergia, MD,Junaid Arshad, MD, MS,Aman Chauhan, MD,Andrew E. Hendifar, MD,Shagufta Shaheen, MD

November 14th 2025

Classification of Neuroendocrine Tumors

Aman Chauhan, MD, of the University of Kentucky

Dr. Chauhan on Future Directions With Lutathera in GEP-NETs

ByAman Chauhan, MD

January 8th 2021

Aman Chauhan, MD, discusses future directions with Lutathera in gastroenteropancreatic neuroendocrine tumors.

Dr. Chauhan on Key Recent Advances in Neuroendocrine Tumors

ByAman Chauhan, MD

October 3rd 2020

Aman Chauhan, MD, a medical oncologist at the University of Kentucky, discusses key recent advances in therapeutics for patients with neuroendocrine tumors, and points to the future with ongoing combination studies.